Article
Liquid biopsy monitoring uncovers acquired RAS-mediated resistance to cetuximab in a substantial proportion of patients with head and neck squamous cell carcinoma.
Oncotarget - 12 Jul 2016
Braig Friederike, Voigtlaender Minna, Schieferdecker Aneta, Busch Chia-Jung, Laban Simon, Grob Tobias, Kriegs Malte, Knecht Rainald, Bokemeyer Carsten, Binder Mascha
Abstract excerpt
Resistance to epidermal growth factor receptor (EGFR)-targeted therapy is insufficiently understood in head and neck squamous cell carcinoma (HNSCC), entailing the lack of predictive biomarkers.Here, we studied resistance-mediating EGFR ectodomain and activating RAS mutations by next-generation sequencing (NGS) of cell lines and tumor tissue of cetuximab-naïve patients (46 cases, 12 cell lines), as well as liquid...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.